진바이오텍
Financials
Valuation Metrics
진바이오텍's Market Cap is ₩409B. At end of 2025 it was ₩345B. Ranked #1898 of 2,421 in KR market (top 78%), #1181 of 1,640 on KOSDAQ (top 72%), #202 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 87%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 40.90B KRW | KR#1,898/2,421 Sec#202/231 |
| Revenue | 89.31B KRW | KR#1,481/2,421 Sec#92/231 |
| Net Income | 3.67B KRW | KR#1,306/2,421 Sec#91/231 |
| Total Assets | 80.28B KRW | KR#1,935/2,421 Sec#160/231 |
| Net Assets | 56.25B KRW | KR#1,824/2,421 Sec#153/231 |
| Employees | 43 | KR#2,109/2,421 Sec#193/231 |
| Value | ||
| P/E | 11.14x | KR#874/2,421 Sec#46/231 |
| P/B | 0.73x | KR#1,169/2,421 Sec#68/231 |
| PEG | 5.44x | KR#814/2,421 Sec#52/231 |
| P/S | 0.46x | KR#862/2,421 Sec#37/231 |
| EV/EBITDA | 10.77x | KR#661/2,421 Sec#32/231 |
| FCF Yield | 9.43% | KR#629/2,421 Sec#28/231 |
| Profitability | ||
| ROE | 6.53% | KR#934/2,421 Sec#64/231 |
| ROA | 4.57% | KR#788/2,421 Sec#62/231 |
| Op. Margin | 5.08% | KR#954/2,421 Sec#71/231 |
| Revenue Growth | 0.97% | KR#1,464/2,421 Sec#144/231 |
| Earnings Growth | 2.05% | KR#813/2,421 Sec#52/231 |
| Financial Health | ||
| Debt Ratio | 42.70% | KR#851/2,421 Sec#99/231 |
| Total Debt | 17.20B KRW | KR#1,433/2,421 Sec#118/231 |
| FCF | 3.86B KRW | KR#967/2,421 Sec#69/231 |
| Cash | 9.23B KRW | KR#1,739/2,421 Sec#151/231 |
| Current Ratio | 3.13x | KR#531/2,421 Sec#74/231 |
| Net Debt/EBITDA | 1.76x | KR#813/2,421 Sec#58/231 |
| Dividend | ||
| Div. Yield | 1.06% | KR#1,104/2,421 Sec#63/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | 8.32% | KR#586/2,421 Sec#37/231 |
| 1M Return | 3.26% | KR#901/2,421 Sec#63/231 |
| From 52W High | -20.70% | KR#267/2,421 Sec#12/231 |
| 1Y MDD | -28.68% | KR#210/2,421 Sec#13/231 |
| Trading | ||
| Volume | 8,093 shares | KR#1,999/2,421 Sec#191/231 |
| Trading Value | 38.6M KRW | KR#1,934/2,421 Sec#195/231 |
| Foreign Own. | 2.52% | KR#1,452/2,421 Sec#136/231 |
| Per Share | ||
| EPS | 426 KRW | KR#1,054/2,421 Sec#73/231 |
| BPS | 6,533 KRW | KR#1,293/2,421 Sec#90/231 |
Company Info
Jin Biotek, established in 2000 and headquartered in Gongju-si, Chungcheongnam-do, was founded to manufacture and sell functional feed additives using beneficial microorganisms, listing on KOSDAQ in 2006. In 2011, it acquired Dawon Chemical Co., Ltd., an animal pharmaceutical company, and supplies natural, eco-friendly feed ingredients and additives based on solid-state fermentation technology. The company focuses on developing technologies and products for environmental improvement, greenhouse gas reduction, and pet food, snacks, and supplements, driven by future technology R&D and ESG management.